ClinicalTrials.gg
RecruitingNCT01499394Updated Jan 21, 2026

Caris Biorepository Research Protocol

An observational study in Cancer, Early Detection of Cancer and Minimal Residual Disease, sponsored by Caris Science, Inc.. Recruiting at 38 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-21.

Primary conditionNeoplasm, ResidualRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Neoplasm, Residual
Why
  1. The study's listed conditions name Neoplasm, Residual, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Caris Science, Inc. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 87 studies in Neoplasm, Residual with a site in United States — 26 open to participants now, 46 under way, 1 of them phase 3. Neoplasm, Residual · United States.

Planned enrollment
Largest of 13
100,000 · median 150
Started
2010
with 2 others
Observational
13 of 87
4 open now
Primary completion
2030-11
later than 37 of 45 live
Registered
9th of 87
by date

Among the 87 studies in Neoplasm, Residual with a site in United States, this one has the largest planned enrollment of the 13 observational ones that give a count, is one of 3 that started in 2010, is one of 13 observational ones, reaches primary completion later than 37 of the 45 other live ones, and was the 9th registered.

Neoplasm, Residual

294 studies on the registry are indexed under Neoplasm, Residual; 137 are open to participants now.

Browse Neoplasm, Residual studies →

Open to participants now

26 of the 87 studies in Neoplasm, Residual with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 93 Neoplasm, Residual studies recruiting now, 59 (63%) set no upper age limit and 24 (26%) stop at 75 or younger; 18 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Neoplasm, Residual with a site in United States, or all of them as a file.
02

Study summary

The Biorepository for Caris Life Sciences is designed for the purpose of making quality biospecimens and associated clinical data available for research studies related to advancing precision medicine and improving care for patients.

The Caris Biorepository is a repository of prospectively collected biological specimens and associated clinical and demographic data gathered from multiple sources to be stored, used and shared for research. Caris Life Sciences will maintain the data and specimens and will control access to and use of the information and specimens by multiple individuals for multiple purposes which may evolve over time.

Read the detailed description

The Caris Biorepository is an effort toward defining the future of medicine incorporating the discoveries of the genomic era by providing physicians, researchers and scientists access to quality human specimens and data aimed at improving human health and fighting disease. This will be accomplished through acquiring and sharing valuable biospecimen information and clinical outcomes in a collaborative, secure environment. The Caris Biorepository will bridge the gap and correlate human specimens with clinical and specimen data valuable to multiple and varying entities interested in advancing science with precision medicine by targeting disease treatments.

The objective of this project is to develop and implement a state-of-the-science Biorepository that ensures molecular integrity and clinical relevance of human biospecimens used in research and clinical medicine. The Caris Biorepository will also provide vital biospecimens and data to internal researchers and external research collaborators such as government, academia and industry collaborators for the use of drug development discoveries, clinically relevant research trials, publications and posters, and the implementation of future healthcare policies. This project may also impact characterization of trends in practice patterns and their relation to patient outcomes as well as the economic implications of differing evaluation, treatment and management paradigms.

03

Conditions studied

  • Cancer
  • Early Detection of Cancer
  • Minimal Residual Disease

Browse trials for

Keywords

  • Caris Biorepository
  • MCED
  • Early Detection
  • MRD
  • Pan-Cancer
04

In context

Neoplasm, Residual Reclassified

294 studies on the registry are indexed under Neoplasm, Residual; 137 are open to participants now.

This study's planned enrollment of 100,000 is above the median of 107 across 88 observational studies indexed under Neoplasm, Residual.

Browse Neoplasm, Residual studies →

Lead sponsor

Caris Science, Inc. is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Compared within Neoplasm, Residual, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy volunteers as well as those with a known disease state or condition

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • Capacity to provide

Exclusion criteria

Exclusion Criteria:

  • Due to the complexity of state and federal requirements governing the participation of prisoners in research, prisoners-patients will not be approached for participation in the Caris Biorepository.
  • Minor subjects will not be included in the Caris Biorepository, as it is possible biospecimens and data may be stored beyond the time limitations of assent and it may be impracticable to re-consent these subjects once they become adults.
  • Individuals who lack the capacity to give
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Normal

    Donor samples reflective of a "normal" non-disease state

  • Newly Diagnosed Pan-Cancer Collection

    Donor samples derived from treatment naïve patients with newly diagnosed solid tumors.

  • Early Detection Collection

    Donor samples reflective of a population at increased risk for developing cancer.

  • Advanced Stage Cancer Collection

    Donor samples derived from individuals with advanced stage cancer.

  • Minimal Residual Disease Collection

    Donor samples obtained from individuals with a history of malignancy who are currently free of active disease

07

What researchers measure

Primary outcomes

  1. Develop biorepository that ensures molecular integrity and clinical relevance of quality human biospecimens and associated clinical data.

    Retention of biospecimen samples with DNA

    Time frame: 35 years

  2. Implement release of specimens from biorepository for testing

    Research for the purposes of cancer laboratory diagnostic tests.

    Time frame: 35 years

Secondary outcomes

  1. Laboratory testing

    DNA and RNA microarray

    Time frame: 35 years

  2. Laboratory testing

    Immunohistochemistry

    Time frame: 35 years

  3. Laboratory testing

    Gene and protein expression, proteomics and matabolomics

    Time frame: 35 years

  4. Laboratory testing

    Mutation analysis

    Time frame: 35 years

  5. Laboratory testing

    Experiemental lab testing for development of new diagnostic technology

    Time frame: 35 years

  6. Laboratory testing

    Microvesicle discovery, characterization and validation.

    Time frame: 35 years

08

Study locations

38 of 38 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Nov 2030 and a completion of Nov 2035. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2011
First posted
Dec 26, 2011
Start
Nov 2010
Primary completionEst.
Nov 2030
CompletionEst.
Nov 2035
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01499394
Lead sponsor
Caris Science, Inc.
Responsible party
Sponsor
First posted
Dec 26, 2011
Start date
Nov 2010
Primary completion
Nov 2030 (estimated)
Completion
Nov 2035 (estimated)
Last update
Jan 21, 2026

Study contacts

Mary Baker
Contact
carisresearch@carisls.com
Matthew Oberley, MD
principal investigator · Caris Life Sciences

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion